Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Mark Jeffrey Delong Sells 363 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 363 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $28.54, for a total value of $10,360.02. Following the transaction, the insider now directly owns 83,945 shares of the company’s stock, valued at $2,395,790.30. This represents a 0.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Apellis Pharmaceuticals Stock Performance

APLS stock traded down $0.42 on Wednesday, hitting $28.11. The company had a trading volume of 453,672 shares, compared to its average volume of 1,777,961. The stock has a market cap of $3.50 billion, a price-to-earnings ratio of -13.83 and a beta of 0.96. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The stock’s 50-day simple moving average is $31.68 and its 200 day simple moving average is $32.41. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $71.90.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on APLS. Wells Fargo & Company lowered their price target on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Scotiabank lowered their target price on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a report on Wednesday, November 6th. Robert W. Baird cut their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Bank of America lowered their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Piper Sandler cut their target price on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Institutional Trading of Apellis Pharmaceuticals

Several large investors have recently modified their holdings of APLS. EverSource Wealth Advisors LLC boosted its stake in shares of Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after acquiring an additional 758 shares during the last quarter. Wolverine Asset Management LLC bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth about $27,000. True Wealth Design LLC bought a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Signaturefd LLC lifted its holdings in Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after purchasing an additional 918 shares in the last quarter. Finally, Capital Performance Advisors LLP bought a new position in shares of Apellis Pharmaceuticals in the third quarter worth approximately $56,000. Institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).